Tryp Therapeutics Inc. (OTCQB:TRYPF) is a clinical-stage biotech company focused on developing psilocybin-based compounds for ill-treated diseases. Together with the University of Florida, the company is currently studying the effects of psilocybin administration on people who suffer from Binge Eating Disorder, a condition for which no treatment has yet proven effective.
Also known as BED, this health condition is characterized by recurring episodes of eating large quantities of food and feeling unable to stop. According to the company, up to 3.5% of females and 2.0% of males will develop this disorder at some point in their lives, which translates to nearly 4 million women and 2 million men in the U.S.
